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1. Introduction  
Long before the existence of cardiovascular imaging, Sir William Osler axiom that “man is as 
old as his arteries”. Followed by several physicians for decades, this aphorism has been 
widely confirmed by studies demonstrating that risk factors for cardiovascular disease 
increase as we age (Cooper et al., 1994; Lakatta & Levy, 2003). Nevertheless, a flaw in this 
statement is the generalization that men and women age similarly. Much data from clinical 
and basic research have established that vascular aging in women does not follow the same 
chronology as in men (Shaw et al., 2006; Pereira et al., 2010; Takenouchi et al., 2009). If 
known risk factors that influence cardiovascular aging are excluded (e.g. smoking, 
cholesterol, hypertension), men display a pattern of progressive vascular aging, while 
timing for vascular aging in women presents a clear hallmark, i.e. menopause (Taddei et al., 
1996; Bucciarelli & Mannucci, 2009). Until menopause women are considered 
“hemodynamically younger” than men, based on epidemiological studies showing that the 
incidence of cardiovascular diseases in premenopausal women is markedly low compared 
to age-matched men (Messerli et al., 1987; Bairey Merz et al., 2006; Shaw et al., 2006). After 
menopause, however, these numbers rise to values that are close, or even higher, to those 
found in men (Lerner & Kannel, 1986; Eaker et al., 1993; Eaker et al., 1994). And so it one 
could say that “man is as old as his arteries, although the arteries of a woman are as young as her 
hormones”. 
Cardiovascular disease is the primary cause of death among women after menopause (55%), 
compared to men (43%) even above all cancers combined (Rosamond et al., 2008). With 
increasing recognition of the importance of cardiovascular disease in women, the interest 
and emphasis on research concerning women and cardiovascular disease have grown 
substantially (Bairey Merz et al., 2006; Shaw et al., 2006). Despite this, there is still a 
concerning gap in the knowledge, understanding, and general awareness of mechanisms for 
cardiovascular aging in women. In this review, we will discuss clinical and experimental 
data that document the effects of aging, estrogens and hormonal replacement therapy on 
vascular function of females. 
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2. Effects of aging on vascular function 
Vascular aging is a natural phenomenon that could be simply described as a consequence of 
physical stress. Arteries are elastic tissues, and as such are predisposed to fatigue and 
fracture with time, as a consequence of extension-relaxation cycles during heartbeats 
(Avolio et al., 1983; Avolio et al., 1985; O'Rourke & Hashimoto, 2007). In fact, fracture of 
elastic lamellae is observed with aging in aorta, and can account for the major physical 
changes seen in elder: dilation (after fracture of load-bearing material) and stiffening (by 
transfer of stress to the more rigid collagenous component of the arterial wall) (Lakatta, 
2003). 
There is growing evidence that vascular aging begins early in life, with evidence for 
alteration in vascular matrix proteins as early as the third decade in health individuals 
(Wallace, 2005; Tracy, 2006; Redheuil et al., 2010). This theory is mathematically supported 
by engineering studies establishing that fatigue and fracture of 10% of natural rubber occurs 
at 8x108 extension-relaxation cycles, which is equivalent to 30 years at a heart rate of 70 
beats/min (O'Rourke & Hashimoto, 2007). Biologically, a combination of imaging and 
histology studies have described age-associated increase in arterial thickening and a 
progressive reduction in aortic strain and distensibility, and have linked those changes to 
increased risk for cardiovascular disease (Lakatta & Levy, 2003; Lakatta, 2003; O'Rourke & 
Nichols, 2005; Redheuil et al., 2010). Although age-associated remodeling of arterial wall has 
been mostly described in patients with established risk for cardiovascular disease, few 
recent studies have shown similar age-related changes in healthy asymptomatic individuals 
(Redheuil et al., 2010). Similar age-related effects on arterial remodeling have been described 
in rodents and non-human primate without risk factors for cardiovascular disease, 
strengthening the hypothesis that aging per se can cause a series of alterations on mechanical 
properties that affect vascular function and lead to subsequent increased risk of 
cardiovascular disease.  
Besides mechanical modifications, aging is also associated with several biochemical changes 
that are also implicated on the development and progression of cardiovascular disease. 
Dysfunction of both endothelial and smooth muscle molecular signaling appear to occur 
during aging process and favors vasospasm, thrombosis, inflammation and abnormal cell 
migration and proliferation (Lakatta, 2003; Briones et al., 2005; Barton, 2010; Herrera et al., 
2010). The presence of endothelial dysfunction in the elder has been largely associated with 
malfunctioning of vascular tissue resulting, in turn, into cardiovascular disease (including 
atherosclerosis, hypertension or coronary artery disease) (Lakatta, 2003; Herrera et al., 2010), 
as well as renal dysfunction (Schmidt et al., 2001; Erdely et al., 2003), Alzheimer (Price et al., 
2004) and erectile dysfunction (Burnett, 2006).  
The mechanisms for age-associated endothelial dysfunction are multiple, though they are 
mostly associated to a decrease on nitric oxide (NO) bioavailability (Hayashi et al., 2008; 
Santhanam et al., 2008; Erusalimsky, 2009; Kim et al., 2009). NO is the major vascular 
messenger molecule involved in many physiological processes, including vasodilation and 
inhibition of thrombosis, cell migration and proliferation (Dudzinski & Michel, 2007; Lamas 
et al., 2007; Michel & Vanhoutte, 2010). Reduced endothelium-dependent and NO-mediated 
vasodilation has been described during aging in both human and animal models (Kim et al., 
2009; Virdis et al., 2010).  
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A lower NO production in elderly may be based in either decreased NO synthesis or 
increased NO degradation. Several mechanisms to explain a reduction on NO production 
have been pointed out and include: 1) a decrease on the expression of endothelial NO 
synthase (eNOS) (Briones et al., 2005; Yoon et al., 2010); 2) a deficiency on NO precursor (L-
arginine) (Santhanam et al., 2008) and eNOS cofactor (tetrahydrobiopterin - BH4) (Yoshida et 
al., 2000; Eskurza et al., 2005); or 3) an increase of endogenous eNOS inhibitors (asymmetric 
dimethylarginine – ADMA) (Xiong et al., 2001; Kielstein et al., 2003). On the other hand, 
strong evidences support the hypothesis that age-associated increase in oxidative stress, and 
consequent production of superoxide anion (O2-) is a potent contributor to lowering NO 
bioavailability and increasing endothelial dysfunction (Jacobson et al., 2007; Rodriguez-
Manas et al., 2009). 
Despite the decline in NO bioavailability could sufficiently explain most of the changes in 
the functioning of vascular cells, other molecules that are crucial to control vascular function 
have also been described to be modified by aging. In the regulation of vasomotion, 
cyclooxygenase (COX)-derived factors are of particular importance as they control both 
vascular relaxation and contraction. Under normal condition, COX-derived relaxing (PGI2) 
and contracting (TXA2 and PGH2) are in perfect balance, and few studies have reported a 
prevalence in the production of relaxing COX factors in the vasculature of young and 
healthy individuals. During aging, however, a swap in this balance favoring to the release of 
contracting factors occurs, leading to an increase of vascular contraction. Moreover, 
activation of inflammatory pathways in the vascular wall plays a central role in the process 
of vascular aging. Several studies have created an important link between arterial aging and 
a pro-inflammatory endothelial phenotype, even in the absence of traditional risk factors for 
atherosclerosis. An age–associated shift to a pro-inflammatory gene expression profile, 
known as endothelial activation, induces up-regulation of cellular adhesion molecules and 
cytokines which increases endothelial–leukocyte interactions and permeability, mechanisms 
considered crucial on the initial steps for the development of atherosclerosis (Herrera et al., 
2010; Seals et al., 2011). 
Even though endothelial function is undoubtedly impaired in the elderly, how aging affects 
molecular biochemistry of vascular cells is largely unknown. Going back to the observation 
that vascular aging is a consequence of mechanical fatigue, one might speculate that the 
mechanical forces on the vascular wall could contribute to the damage on endothelial cell 
functioning. In fact, it is well known that blood vessels are under constant mechanical 
loading from flowing blood which cause internal stresses, known as endothelial shear stress 
(caused by flow) and circumferential stretch (caused by pressure). These mechanical forces 
not only cause morphological changes of endothelium and blood vessel wall, but also 
trigger a myriad of intracellular events in endothelial cells and activate biochemical and 
biological events (Lu & Kassab, 2011). The triggering of endothelial signaling by mechanic 
forces seems to be mostly determined by the cytoskeleton, which represents a highly 
dynamic network that constantly assembles and disassembles, playing an active role in 
responding to mechanical stimuli (Wong et al., 1983). The cytoskeleton rearranges upon 
changes on stress and stretch and activates signaling molecules, such as NO production, that 
are capable to regulate vascular tone in order to keep homeostasis (Su et al., 2005; Su et al., 
2007). An increase in arterial wall stiffening by aging could alter the impact of a mechanical 
stimulus, and therefore induce a significant reduction or dysfunction in the signaling 
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pathways activated by shear stress (Kliche et al., 2011). In this regard, the chronically stiffed 
cells will lead to a decrease of NO, which will eventually lead to endothelial dysfunction. 
Continuous damage to the endothelium from the daily pounding of the cycling pressure can 
also activate maintenance repair systems. When maintenance system is efficient (as in young 
individuals), endothelial cells likely correct the defect and keep going. On the other hand, 
when an irreversible damage occur or when endothelial cells are senescent, those inefficient 
cells are eventually eliminated by a mechanism yet to be described, while a “sister” 
circulating progenitor endothelial cells assume some repair function and will divide to fill 
up the gap (Thorin & Thorin-Trescases, 2009). Recent findings on progenitor stem cell 
research suggest that continuous division of progenitor endothelial cells for maintenance is 
likely the main response of an injured endothelium (Hill et al., 2003; Van Craenenbroeck & 
Conraads, 2010). Continuous cell division during life causes shortening in telomeres, a 
region of repetitive DNA sequences at the end of a chromosome, which protects the 
chromosomes from deterioration (Allsopp et al., 1995). Increasing evidence have support a 
role for reduction on telomere length with changes on cellular function and cellular 
senescence that may contribute to increased risk of vascular damage. In the long term, 
therefore, the regenerated endothelium may become dysfunctional as senescent endothelial 
cells start to express a pro-inflammatory, pro-oxidative, and pro-atherogenic phenotype 
(Chang & Harley, 1995; Bekaert et al., 2007; De Meyer T. et al., 2011). 
In addition to mechanical fatigue, the vascular endothelium also undergoes important 
oxidative damage. The free-radical theory of aging states that organisms age because cells 
accumulate oxidative stress damage over time (de Grey, 2006; Camici et al., 2011). In other 
words, one can say that the body literally “rusts” with time. Growing evidence from 
research studies have supported this theory and have described an intimate relationship of 
increased oxidative stress with vascular dysfunction and increased risk for cardiovascular 
disease (Touyz, 2003; Griendling & Alexander, 1997; Harrison, 1997). Numerous studies 
underscore the importance of dysregulated oxidant and antioxidant balance in advancing 
age (Moon et al., 2001) and in the development and progression of atherosclerosis 
(Wassmann et al., 2004). Aging-associated increase in reactive oxygen species (ROS) are 
common to many species and despite decades of investigation, the mechanisms for the 
aging-related increase in ROS and how they affect vascular function have yet to be defined.  
The main ROS proposed to be implicated on vascular aging process is the O2-. Increased O2- 
in the vessel wall has been well associated with decrease of NO bioavailability due to its 
rapid interaction and inactivation by O2-. In this regard, an increase of oxidative stress, and 
more specifically O2-, during aging could cause vascular damage simply by reducing the 
protective effect of NO in the vessel wall (Squadrito & Pryor, 1998; Harrison, 1997). 
However, increased oxidative stress has been implicated in more complex modulatory 
mechanisms that may affect vascular function by aging. Numerous studies have 
demonstrated that increase of oxidative stress contributes to the activation of transcriptional 
factors (such as NF-κB) that are key regulators of endothelial activation. By this way, aging-
associated increase of ROS could favor endothelial cells to express a pro-inflammatory 
phenotype and increase the risk for cardiovascular disease (Herrera et al., 2010).  
But proper vascular function does not lean on endothelium only. Vascular smooth muscle 
cells comprised by medial layer of blood vessels represent a dynamic component of the 
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vasculature, and thus may also be affected by aging. In fact, vascular smooth muscle cells 
degenerate and decrease in number when subjects reach middle or advanced age. Smooth 
muscle cells are intercalated between the elastic lamina and the elastic fibers that also 
undergo a process of degeneration, thinning, sectioning, fracture and decrease in volume 
with aging. In parallel, there is a marked increase on collagen fibers, mucinous substrate, 
and calcification of the intercellular substrates begins (Toda et al., 1980).  
Biochemical studies have shown that the content of elastin in human aorta decreases with 
age (Spina et al., 1983). Large amounts of elastin are produced during the fetal or neonatal 
period but not later (Godfrey et al., 1993). An age-related decrease in the cross-links in 
elastin contributes significantly to the reduction in arterial elasticity (Watanabe et al., 1996). 
As the turnover of elastin and collagen requires a very long period of time (lasting more 
than 10 years), these molecules are likely to undergo the addition of a sugar or a 
glycooxidative reaction. Thus, advanced glycation end-products accumulate in the arteries 
with age and partially contribute to age-related arterial stiffness (Konova et al., 2004; Semba 
et al., 2009). Type I, III, and V collagens are the major components of the collagen fibers of 
large conductance vessels such as aorta. During infancy or early childhood, collagen fibers 
are absent in the aorta and begin to accumulate with age; this process is known as fibrosis or 
sclerosis. Most studies have shown an age-related increase in the collagen content in the 
aorta (Spina et al., 1983) and increase in the number of collagen cross-links (Watanabe et al., 
1996). Both an increase in the collagen content and the number of cross-links contributes 
significantly to the stiffening of the elastic arteries, namely atherosclerosis. 
Senescent vascular smooth muscle cells have been shown to exhibit a pro-
calcificatory/osteoblastic phenotype (Reid & Andersen, 1993; Burton, 2009; Nakano-
Kurimoto et al., 2009), that could play a major role in the pathophysiology of age-related 
vascular calcification, a well-known major risk factor for the development of cardiovascular 
diseases (Adragao et al., 2004; Thompson & Partridge, 2004). Calcification in tunica media 
(medial calcification) increases throughout ageing, and accumulation of calcium in the 
elastin-rich layer of the media is ≥30-times more in the thoracic aorta at 90 years of age than 
that at 20 years of age (Elliott & McGrath, 1994). The underlying mechanisms that lead to the 
development of vascular calcification currently remain elusive. Calcification in the media 
usually occurs in the absence of macrophages and lipids, and is associated with -smooth 
muscle actin-positive vascular smooth muscle cells, suggesting that vascular smooth muscle 
cells are the main key player in medial calcification (Luo et al., 1997). Alternatively, ROS 
may have some involvement in the osteoblastic transition of vascular smooth muscle cells 
(Byon et al., 2008). 
Researchers have examined the role of the redox state in vascular smooth muscle cells in the 
pathogenesis of vascular disease (Clempus & Griendling, 2006; Lyle & Griendling, 2006). 
Vascular smooth muscle cells present in atherosclerotic lesions proliferate more rapidly and 
show increased expression of genes for growth factors and other molecules involved in 
extracellular matrix remodeling (Schwartz, 1997; Newby, 2006). Proliferation of vascular 
smooth muscle cells is part of the initiation and the progression of atherosclerosis (Ross, 
1993) and may occur in response to injury or as a result of aberrant apoptosis (Clarke et al., 
2006). Besides, vascular smooth muscle cells appear to undergo an age-associated 
phenotypic modulation toward a dedifferentiated and synthetic state. Smooth muscle cell 
migration from the medial to the intimal compartment is a plausible mechanism for the 
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increased number of vascular smooth muscle cells within the diffusely thickened intima of 
central arteries as animals age (Miller et al., 2007). 
In general, growth factors and hormones are the most potent activators that stimulate 
vascular smooth muscle growth, migration, and extracellular matrix synthesis. For instance, 
angiotensin II (Ang II) signaling has been widely linked to an age-associated increase in the 
migratory capacity of vascular smooth muscle cells and to the proinflammatory features of 
arterial aging. Ang II increases within the aged arterial wall and activates matrix 
metalloproteinase type II (MMP2) (Wang et al., 2003; Jiang et al., 2008). Ang II appears to 
initiate growth-promoting signal transduction through ROS-sensitive tyrosine kinases 
(Frank & Eguchi, 2003; Touyz et al., 2003).  
3. Gender differences on vascular aging 
Although arteries from females are so exposed to mechanical and oxidative damage as 
arteries from males, they seem do not follow the same time course for vascular aging, or 
at least, they do not age in the same way. Experimental and clinical studies support the 
hypothesis that men are hemodynamically older than age-matched, premenopausal 
women (Messerli et al., 1987; Bairey Merz et al., 2006; Shaw et al., 2006). With aging, the 
progression of cardiovascular disease occurs at an earlier age and become more severe in 
males compared to age-matched premenopausal females (Taddei et al., 1996; Virdis et al., 
2010).  
Arterial stiffening and distensibility are established markers for vascular aging and have 
been found to progressively increase with aging in both men and women. Studies in rodents 
indicate that there are gender differences in aging vessels, with stiffness increasing more in 
male than in females (Ruiz-Feria et al., 2009; Chan et al., 2011). Also in nonhuman primates, 
aortic stiffness has shown to be increased more in old male monkeys than in old females 
(Qiu et al., 2007). However, gender-associated relationship with those markers in humans 
remains unclear and currently limited studies have addressed to the evaluation of age-
related vascular changes in man and women separately. Even though, many studies have 
performed their analysis on aging correlation with arterial stiffness and distensibility in men 
and women separately, their statistical models generally mask the gender differences in the 
influence of these variables (Breithaupt-Grogler & Belz, 1999; Segers et al., 2007; Redheuil et 
al., 2010; Miyoshi et al., 2011). In most clinical studies using small population group, the 
data do not provide sufficient power to detect significant gender-related differences in the 
rate of age-dependent change in vascular wall structure. The field still misses a large multi-
centric populational study to identify whether aging-related effects are modulated by 
gender. 
When it comes to the endothelium, sexual dimorphism on endothelial dysfunction and the 
progression of cardiovascular disease has also been well documented in various animal 
models (Ouchi et al., 1987; Ashton & Balment, 1991; Dantas et al., 2004a). With aging, males 
exhibit signals of impairment on endothelium-dependent relaxation at earlier age than do 
females (Kauser & Rubanyi, 1995; Huang et al., 1997). Thus far, the mechanisms better 
established to explain the gender- and aging-associated differences involve: 1) increased NO 
production by females (Huang et al., 1997); and 2) increased oxidative stress in male blood 
vessels (Dantas et al., 2004a). In this area of age-associated effects, a translation of animal 
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models to humans can be performed. Early clinical studies on gender- and aging-related 
effects on endothelium-dependent relaxation in forearm blood flow have identified a 
constant age-related decline in maximal vasodilation to acetylcholine per year (Taddei et al., 
1996). In contrast, women were found to show a slight decrease per year in vasodilation to 
acetylcholine up to middle-age (around 50’s). After that, the vascular decline in the 
responses to the endothelium-dependent vasodilator hasten, and even decline more quickly 
in comparison with men (Taddei et al., 1996).  
Gender modulation of vascular tone is also observed in functional studies. Contractile 
responses are greater in the aorta of male than female rats (Stallone et al., 1991; Crews et al., 
1999; Tostes et al., 2000). These differences may be related to the vasodilatory effects of 
estrogens (Crews et al., 1999; Kanashiro & Khalil, 2001) through a direct action on vascular 
smooth muscle (Jiang et al., 1992; Mugge et al., 1993; Gerhard & Ganz, 1995; Crews & Khalil, 
1999). Expression of estrogen receptors in smooth muscle may vary depending on the 
gender and the gonadal status (Tamaya et al., 1993). The decreased vascular responses to 
constrictors may be related to 1) the higher relative abundance of estrogen receptors in 
females arteries (Collins et al., 1995), 2) estrogen-induced down-regulation of gene 
expression of vasoconstrictor receptors, such as Ang II (Nickenig et al., 2000), and 3) 
signaling mechanisms of vascular smooth muscle contraction downstream from receptor 
activation. 
As intracellular free Ca2+ concentration ([Ca2+]i) is important for the initiation of smooth 
muscle contraction (Horowitz et al., 1996), several studies have used isolated vascular 
preparations and smooth muscle cells from control and gonadectomized male and female 
animals to investigate the effect of estrogen on [Ca2+]i and the Ca2+-mobilization 
mechanisms (i.e. Ca2+ release from the intracellular stores and Ca2+ entry from the 
extracellular space) (Zhang et al., 1994; Crews & Khalil, 1999; Crews et al., 1999; Murphy & 
Khalil, 1999; Murphy & Khalil, 2000; Novella et al., 2010). 
Taken together those studies can suggest that, with aging, women are more protected 
against its deleterious consequences in the cardiovascular system than men. After 
menopause, however, this protection seems to be lost, since the incidence of cardiovascular 
disease increases considerably to levels similar (or higher) to those found in men. Because 
the onset of menopause is marked by the loss of endogenous estrogen production from the 
ovaries, estrogen is felt to confer the premenopausal protection. 
4. Vascular aging in females: Effects of estrogen on vascular function and 
aging 
In women, arterial aging includes an aggravating risk factor in comparison to men. The 
decrease in estrogen production by menopause is thought to contribute to increased 
cardiovascular risk. Although aging per se has detrimental effects in the vasculature of 
middle aged female, these effects seem to be potentiated by the lack of estrogen with 
menopause, and restored by estrogen replacement (Harman, 2004; Stice et al., 2009; Novella 
et al., 2010). For this reason it is particularly difficult to distinguish what would be the 
contribution of aging and the lack of estrogen in the control of vascular function in 
menopausal women.  
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Epidemiological observations and extensive basic laboratory research has shown that female 
sex hormones, and more specifically estrogen, has direct beneficial effects in the 
cardiovascular system (Staessen et al., 1989; Dantas et al., 1999; Tostes et al., 2003; Dantas et 
al., 2004b; Hinojosa-Laborde et al., 2004). Estrogen has been described to display a myriad of 
metabolic, hemodynamic, and vascular effects, which have been largely associated to 
cardiovascular protection in females. For instance, estrogen can promote cardiovascular 
protection by indirectly influence on the metabolism of lipoproteins or directly by acting on 
the modulation of molecular pathways in the vessel wall (Miller & Duckles, 2008). Receptors 
for estrogen have been identified biochemically and show a plentiful expression in both 
vascular smooth muscle and endothelium, reinforcing the idea that estrogen play a key role 
in the control of vascular function (Couse et al., 1997; Pau et al., 1998; Arnal et al., 2010). 
When considering the major structural changes caused by aging, cross-sectional studies 
have shown that postmenopausal females taking hormone replacement therapy present 
lower arterial stiffness compared with their peers not taken estrogen (Moreau et al., 2003; 
Sumino et al., 2005; Sumino et al., 2006). Besides, radial artery distensibility fluctuates in 
accordance with estrogen levels during menstrual cycles (Giannattasio et al., 1999). Basic 
research using animal models for estrogen withdrawn and aging have proposed that 
estrogen play a modulatory role in the molecular mechanisms to prevent stiffening of 
arterial wall. As mentioned above, content of collagen and elastin into arterial wall is a key 
factor that contributes to arterial wall thickening and stiffening, and is mostly regulated by 
the activity of matrix metalloproteinases (MMP), a family of enzymes capable of degrading 
components of the extracellular matrix. During aging there is a marked decrease of MMP 
activity which results in increase of collagen accumulation and consequent stiffening. Data 
from studies in female rodents have found that estrogen replacement in ovariectomized 
animals increases MMP activity and restores structural properties of aged arteries similar to 
that of the young group (Zhang et al., 2000). Altogether these studies suggest that estrogen 
can exert a favorable modulatory effect on arterial stiffness with aging in females.  
Endothelial dysfunction secondary to estrogen deprivation has been largely described and 
has been mostly associated with reductions in NO availability. Estrogen is known to 
increases NO bioavailability by mechanisms that involve either increase of NO generation 
directly or by decreasing O2- concentration, and thereby attenuating O2- mediated 
inactivation of NO. The mechanisms involved in estrogen-induced increases in NO 
availability include: 1) transcriptional stimulation of endothelial NO synthase (eNOS) gene 
expression (Huang et al., 1997; Sumi & Ignarro, 2003); 2) non-genomic activation of enzyme 
activity via a phosphatidylinositol-3-OH kinase (PI3-kinase)/phosphokinase B (PKB/AKT) 
mediated signaling pathway (Hisamoto et al., 2001); 3) increased [Ca2+]i in endothelial cells 
(Rubio-Gayosso et al., 2000); 4) decreased production of eNOS endogenous inhibitor, 
ADMA (Monsalve et al., 2007), and 5) attenuated O2- concentrations (Wassmann et al., 2001; 
Dantas et al., 2002; Ospina et al., 2002).  
In addition to NO, actions of estrogen in the vasculature also influence the metabolism of 
other endothelium-derived factors (EDF). Estrogen has been described to positively up-
regulate the production of endothelium-derived relaxing factors (EDRF), such as PGI2 
(Sobrino et al., 2009; Sobrino et al., 2010) and the endothelium-derived hyperpolarizing 
factors (EDHF) (Golding & Kepler, 2001), both of which are important mediators of vascular 
relaxation in resistance-sized arteries. Concomitantly, a modulating role of estrogen on 
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constrictor factors (EDCF) is observed. Studies have shown that the beneficial effects of 
estrogen on the endothelium can be partially explained by an inhibitory effect on the 
production or action of the COX-derived vasoconstrictor agents (PGH2 and TXA2) (Davidge 
& Zhang, 1998; Dantas et al., 1999; Novella et al., 2010) and endothelin- 1 (ET-1) (David et 
al., 2001).  
Estrogen has been shown to be a modulator of contractile responses by directly interfering 
with Ca2+ into the vascular smooth muscle cells. Although some studies have shown that 
estrogen does not inhibit Ca2+ release from the intracellular stores (Crews & Khalil, 1999; 
Murphy & Khalil, 1999), others have described that, supraphysiological concentrations of 
estrogen inhibit Ca2+ influx from the extracellular space (Han et al., 1995; Crews & Khalil, 
1999; Murphy & Khalil, 1999) by inhibiting Ca2+ entry through voltage-gated Ca2+ channels 
(Freay et al., 1997; Kitazawa et al., 1997; Crews & Khalil, 1999; Murphy & Khalil, 1999). The 
expression of the L-type Ca2+ channels in cardiac muscle is substantially increased in 
estrogen receptor-deficient mice (Johnson et al., 1997), suggesting that estrogen may 
regulate Ca2+ mobilization by a receptor-mediated system.  
Although a genomic action of physiological concentrations of estrogen on the expression of 
the Ca2+ channels may underlie the reduced cell contraction and [Ca2+]i observed in vascular 
smooth muscle cells of females, it is less likely to account for the acute inhibitory effects of 
17-estradiol on cell contraction and [Ca2+]i in vitro. The acute nature of the vasorelaxant 
effects of exogenous estrogen may represent additional non-genomic effects of estrogen on 
the mechanisms of Ca2+ entry into vascular smooth muscle (Kitazawa et al., 1997; Crews & 
Khalil, 1999; Murphy & Khalil, 1999). Whether estrogen inhibits Ca2+ entry by a direct or 
indirect action on plasmalemmal Ca2+ channels remains unclear. Some studies have shown 
that estrogen blocks Ca2+ channels in smooth muscle cells (Zhang et al., 1994; Nakajima et 
al., 1995) and others have shown that estrogen activates large conductance Ca2+-activated K+ 
channels, which could lead to hyperpolarization and decreased Ca2+ entry through voltage-
gated channels (White et al., 1995; Wellman et al., 1996). Estrogen may also decrease [Ca2+]i 
by stimulating Ca2+ extrusion via the plasmalemmal Ca2+ pump (Prakash et al., 1999). 
However, this mechanism seems less likely because the rate of decay of [Ca2+]i transients in 
smooth muscle incubated in Ca2+-free solution are not affected by estrogen (Crews & Khalil, 
1999; Murphy & Khalil, 1999).  
Other systems critically involved in the control of vascular function are also known to 
undergo estrogen modulation. For example, estrogen has been described to exert direct 
modulation on the components of renin-angiotensin system (RAS), which is a key regulator 
of blood pressure and smooth muscle cell growth. Estrogen reduces production of the active 
hormone of the RAS, Ang II in part, by inhibiting angiotensin-converting enzyme (ACE) 
expression. ACE activity in the circulation and in tissues, including the kidney and aorta, is 
reduced upon chronic estrogen replacement in animal models of menopause as well as in 
postmenopausal women (Brosnihan et al., 1999; Seely et al., 2004). Furthermore, estrogen 
attenuates the expression and tissue response to type 1 (AT1) angiotensin receptor in several 
cardiovascular tissues including the aorta, heart and kidney (Silva-Antonialli et al., 2000; Wu 
et al., 2003).  
Because increased oxidative stress play a crucial role on aging-associated vascular damage, 
numerous studies have assessed the antioxidant potential of estrogens. Basic research in 
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human cultured endothelial cells revealed an antioxidant effect of estradiol (Hermenegildo 
et al., 2002a). In addition, clinical experimental studies have shown that different estrogens 
are capable of reducing oxidation of LDL- cholesterol and consequently the development of 
atherosclerosis (Keaney, Jr. et al., 1994; Shwaery et al., 1998; Hermenegildo et al., 2001; 
Hermenegildo et al., 2002b). In addition to its antioxidant role, estradiol exerts a direct effect 
by restoring the ADMA levels rise induced by oxidized LDL in human cultured endothelial 
cells acting through estrogen receptor . Estrogen also attenuates the deleterious effects 
induced by increased generation of ROS follow ischemia/reperfusion in distinct research 
models (Kim et al., 1996; Kim et al., 2006; Guo et al., 2010).  
As a result of their phenolic molecular structure, several estrogens, such as 17-estradiol, 
estrone or estriol, have been described to act as ROS scavengers by virtue of the hydrogen-
donating capacity of their phenolic groups (Halliwell & Grootveld, 1987; Dubey & Jackson, 
2001). However, in these studies the direct effect of estrogens as scavenger can only be 
observed at concentrations above 1 micromolar (Arnal et al., 1996; Kim et al., 1996). 
Considering that plasma concentrations of estrogen in physiological conditions are in the 
nanomolar range is likely that the direct action as a scavenger is not the main anti-oxidant 
mechanism by estrogen. In fact, studies have established that estrogen modulates ROS 
concentration a mechanism that involves interaction with its nuclear receptor to decrease 
oxidative proteins and/or increase antioxidant enzymes expression. Many studies have 
shown that changes in estrogen levels are associated with altered levels of anti-oxidant 
enzymes including glutathione peroxidase, catalase and superoxide dismutase (Capel et al., 
1981; Robb & Stuart, 2011; Sivritas et al., 2011). Moreover, recent studies have shown a 
modulatory effect of estrogen on O2-, via modulation of NADH/NADPH oxidases and AT1 
receptor gene expression (major sources of O2- production) (Wassmann et al., 2001; Dantas et 
al., 2002). 
Among all research on cellular aging process and its complication, there is a growing 
interest on mechanisms to delay or decrease telomere shortening by aging, and therefore, 
keeping cellular integrity and function (Allsopp et al., 1995). In this sense, few studies have 
explored the effects of estrogen on telomere shortening, and even fewer have addressed this 
issue in association with vascular aging. Mechanistic studies have found that estrogen 
treatment up-regulates transcription of hTERT, the catalytic subunit of human telomerase, 
in distinct cell lines, including endothelial cells (Farsetti et al., 2009). Intriguingly, activation 
of hTERT by NO signaling has also been reported (Vasa et al., 2000). Considering that 
estrogen augments NO production, one can suggest that estrogens doubly prevent vascular 
senescence: by directly interacting with its receptor and by increasing NO. 
Although estrogen modulates several mechanisms that are closely associated with vascular 
aging, assuming that estrogen put a break on vascular aging in females would be rather 
speculative. There is no sufficient data available to correlate estrogen levels with a delay on 
progression of vascular aging and recent clinical trials have questioned the value of estrogen 
replacement therapy in protecting vascular function. The benefits of hormone replacement 
therapy on the life expectancy and vascular health of women have dramatically lost 
consensus since publication of the results of the Women's Health Initiative study (WHI) 
(Rossouw et al., 2002). The WHI trial did not find any cardiovascular benefit from estrogen 
in postmenopausal women and in fact, showed hormone replacement therapy was 
associated with increased risk to the cardiovascular system (Rossouw et al., 2002). 
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There is much controversy over the interpretation of WHI. Concerns raised include that the 
estrogens used in those trials are not naturally occurring and thus would not act identically 
to natural estrogens. Most importantly was the fact that the WHI, as well as the majority of 
clinical trial on hormone replacement therapy, studied a population of women that were 
estrogen deficient for, on average, 10 years before hormone replacement was initiated. 
Currently, it is not known if the vascular effects of estrogen are modified by aging in 
females. These observations, together with observational studies, have led scientists to 
create the so-called “timing hypothesis”. This theory states that estrogen-mediated benefits 
to prevent cardiovascular disease only occur when treatment is initiated before the 
detrimental effects of aging are established on vascular wall (Harman, 2006). In this regard, 
few recent basic studies have shown that aging is associated with significant reductions in 
the direct estrogen-mediated mechanisms of vascular relaxation (Wynne et al., 2004; LeBlanc 
et al., 2009; Lekontseva et al., 2010). The lack of estrogen responses in those animals was not 
related to age-associated changes in the plasma levels of estrogen or activity of estrogen 
receptors, but rather by possible age-related changes in estrogen-mediated signaling 
pathways in the vasculature.  
Moreover, recent clinical studies have revealed that different risk factors for cardiovascular 
disease in postmenopausal women were lower among women 50 to 59 years old at 
enrolment for estrogen replacement therapy (Manson et al., 2007; Sherwood et al., 2007). 
Nevertheless, the field lacks detailed research on the long-term effects by estrogen and how 
it modulates cardiovascular function during aging. It remains unclear to what extent the 
protective effects of estrogen replacement well described in young females can be 
extrapolated to older ones. The aging issue still needs to be addressed in both experimental 
and clinical studies, and together, these studies demonstrate that estrogen has complex 
biologic effects and may influence the risk of cardiovascular events and other outcomes 
through multiple pathways. Therefore aging of a giving organism should always be taken 
into account when the pharmacological and physiological responses by estrogens are 
determined. 
5. Conclusion 
We live in an aging society, with life expectancy far greater today than a century ago. The 
increasing incidence of older-age people in our society represents the culmination of 
centuries of medical, scientific, and social accomplishments. The challenge for modern 
medicine is how to increase the number of disease-free years in elderly people and improve 
quality of life in later years. However, a disproportionate number of people who reach old 
age suffer from cardiovascular diseases.  
Clinical and basic studies have established that vascular aging in women does not follow the 
same chronology as in men. Men display a pattern of progressive vascular aging, while 
timing for vascular aging in women presents a clear hallmark, i.e. menopause. Several 
studies have shown that the incidence of cardiovascular diseases in premenopausal women 
is markedly low compared to age-matched men. After menopause, however, these figures 
increase to values that are close, or even higher, to those found in men. Cardiovascular 
disease is the primary cause of death among women after menopause. Despite this, there is 
still a concerning gap in the knowledge, understanding, and general awareness of 
mechanisms for cardiovascular aging in women.  
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It has become apparent that to improve diagnosis and treatment of vascular aging, the 
gender differences in cardiovascular control must be addressed. The impact of the 
menstrual cycle and hormonal replacement therapy on vascular function of females should 
also be taken into consideration. Different strategies have shown benefit in preventing, 
delaying or attenuating vascular aging. Nevertheless, it yet remains to be fully 
demonstrated whether vascular aging can be pharmacologically prevented. Further research 
efforts are needed to understand the causes and consequences of female vascular aging and 
propose new therapeutic strategies for the management of vascular senescence in women. 
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